Epic Sciences Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 88
Employees
  • Latest Deal Type
  • Debt - PPP
  • Latest Deal Amount
  • $1.92M
Latest Deal Amount
  • Investors
  • 21

Epic Sciences General Information

Description

Developer of diagnostic tests technology intended to help the rapid and non-invasive detection of genetic and molecular changes in cancer throughout. The company's technology not only assesses the number of circulating tumor cells and its subtypes but also profiles single-cell phenotype and genotype as well as provide near real-time information about each different cellular population before, during and after treatments-with no cell left behind, enabling oncologists to identify and analyze rare disease cells from a tube of blood that also contains millions of normal cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Primary Office
  • 9381 Judicial Drive
  • Suite 200
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Epic Sciences Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Epic Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Debt - PPP 14-Apr-2020 $1.92M 00000 Completed Generating Revenue
11. Later Stage VC (Series E) 12-Sep-2018 0000 00000 00000 Completed Generating Revenue
10. Debt - General 01-Aug-2017 0000 00000 Completed Clinical Trials - General
9. Later Stage VC (Series D) 28-Apr-2017 0000 00000 0000 Completed Clinical Trials - General
8. Later Stage VC (Series C1) 23-May-2016 00.000 0000 000.00 Completed Clinical Trials - General
7. Debt - General 01-Jun-2015 0000 000.00 Completed Clinical Trials - General
6. Later Stage VC (Series C) 30-Jul-2014 0000 000.00 000.00 Completed Clinical Trials - General
5. Early Stage VC (Series B) 13-Nov-2012 0000 000.00 000.00 Completed Clinical Trials - General
4. Grant 01-Jan-2012 $1000K $4.26M Completed Product Development
3. Early Stage VC (Series A) 31-Mar-2011 $1.76M $4.26M 000.00 Completed Product Development
To view Epic Sciences’s complete valuation and funding history, request access »

Epic Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series D 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series C1 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
Series B1 16,003,560 $0.000100 $0.04 $0.56 $0.56 1x $0.56 6.65%
Series A1 6,050,104 $0.000100 $0.02 $0.28 $0.28 1x $0.28 2.51%
To view Epic Sciences’s complete cap table history, request access »

Epic Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of diagnostic tests technology intended to help the rapid and non-invasive detection of genetic and molecular
Biotechnology
San Diego, CA
88 As of 2020
00000
000000000 - 00000

00000000

ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolo
0000000000 000000000
Tolochenaz, Switzerland
00 As of 0000
000.00
000 0000-00-00
00000000000 000.00

00000000

iat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deseru
0000000000 000000000
Thousand Oaks, CA
0 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Epic Sciences Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lunaphore Technologies Venture Capital-Backed Tolochenaz, Switzerland 00 000.00 00000000000 000.00
00000000 00 Venture Capital-Backed Thousand Oaks, CA 0 000.00 0000000000 0 000.00
00000 Venture Capital-Backed Menlo Park, CA 000 000 000000&0 000
0000000000 Venture Capital-Backed Pittsburgh, PA 00 00.00 00000000000 00.00
000000000 00000 Venture Capital-Backed Siena, Italy 00 0000000000 0
You’re viewing 5 of 36 competitors. Get the full list »

Epic Sciences Executive Team (20)

Name Title Board Seat Contact Info
Lloyd Sanders Chief Executive Officer, Board Member & President
Jorge Nieva Co-Founder
Joel Smith JD Chief Financial Officer & General Counsel
Ryan Dittamore Chief of Medical Innovation and Head of Translational Research Partnerships
Dena Marrinucci Ph.D Co-Founder & Member Clinical Advisory Board
You’re viewing 5 of 20 executive team members. Get the full list »

Epic Sciences Board Members (11)

Name Representing Role Since
Andrew ElBardissi MD Deerfield Management Board Member 000 0000
Charles Kennedy MD Blue Ox Healthcare Partners Board Member 000 0000
Gary Gong Self Board Member 000 0000
Gregory Critchfield MD Self Board Member 000 0000
Gregory Lucier Self Chairman 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Epic Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Epic Sciences Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Blue Ox Healthcare Partners Growth/Expansion Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
LabCorp Ventures Corporate Venture Capital Minority 000 0000 000000 0
Varian Other Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 21 investors. Get the full list »